Currently out of the existing stock ratings of Joseph Pantginis, 1177 are a BUY (97.6%), 28 are a HOLD (2.32%), 1 are a SELL (0.08%).

Joseph Pantginis

Work Performance Price Targets & Ratings Chart

Analyst Joseph Pantginis, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 45.58% that have a potential upside of 53.01% achieved within 353 days. Previously, Joseph Pantginis worked at ROTH MKM.

Joseph Pantginis’s has documented 2,109 price targets and ratings displayed on 105 stocks. The coverage is on Healthcare, Industrials, Energy, Technology, Utilities sectors.

Most recent stock forecast was given on NVCT, Nuvectis Pharma at 22-Jun-2026.

Wall Street Analyst Joseph Pantginis

Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for CDTX (CIDARA THERAPEUTICS) at 6/18/2025. The price target of $41 was fulfilled within 5 days with a profit of $19.69 (92.4%) receiving and performance score of 184.8.

Average potential price target upside

of $221.2 (144.54%) on PIRS (PIERIS PHARMACEUTICALS).
of $138.28 (70%) on APTO (APTOSE BIOSCIENCES).
of $125 (55.73%) on MBIO (MUSTANG BIO).

ADRO Aduro Biotech ATNM Actinium Pharmaceuticals CAPR Capricor Therapeutics CLBS Caladrius Biosciences LCTX Lineage Cell Therapeutics PTN Palatin Technologies REGN Regeneron Pharmaceuticals SSKN STRATA Skin Sciences XBIO Xenetic Biosciences AGTC Applied Genetic CYTK Cytokinetics LGND Ligand Pharmaceuticals VSTM Verastem APTO Aptose Biosciences CLDX Celldex Therapeutics DBTX Decibel Therapeutics IOVA Iovance Biotherapeutics KRYS Krystal Biotech KURA Kura Oncology LIFE aTyr Pharma PHGE Biomx PROG Progenity RIGL Rigel Pharmaceuticals BCDA Biocardia BYSI BeyondSpring KDNY Chinook Therapeutics SIOX Sio Gene Therapies VYNE Vyne Therapeutics XOMA XOMA Corp CLNN Clene CMPX Compass Therapeutics BMEA Biomea Fusion CKPT Checkpoint Therapeutics IMV IMV ARAV Aravive ARMP Armata Pharmaceuticals ATXS Astria Therapeutics BCEL Atreca BNOX Bionomics Ltd ADR BPTS Biophytis ESPR Esperion Therapeutics GNTA Genenta Science SpA ADR MDGL Madrigal Pharmaceuticals NVCT Nuvectis Pharma PDSB PDS Biotechnology Corp STTK Shattuck Labs TNYA Tenaya Therapeutics TPST Tempest Therapeutics SNSS Sunesis Pharmaceuticals TGTX TG Therapeutics ALPN Alpine Immune Sciences APRE Aprea Therapeutics BLRX BioLineRx Ltd MBIO Mustang Bio ONTX Onconova Therapeutics PBLA Panbela Therapeutics VKTX Viking Therapeutics AKUS Akouos CDMO Avid Bioservices CNCE Concert Pharmaceuticals CRIS Curis PRNB Principia Biopharma PSTV Plus Therapeutics GNCA Genocea Biosciences SPHS Sophiris Bio SRRA Sierra Oncology STML Stemline Therapeutics VBLT Vascular Biogenics Ltd LXRX Lexicon Pharmaceuticals ATYR aTyr Pharma ANL Adlai Nortye Ltd. American Depositary Shares CALC CalciMedica, Common Stock CVKD Cadrenal Therapeutics, Common Stock OABI OmniAb PHAR Pharming Group NV PIRS Pieris Pharmaceuticals CATB Catabasis Pharmaceuticals ENLV Enlivex Therapeutics Ltd HTBX Heat Biologics MEIP MEI Pharma FGEN FibroGen RTRX Travere Therapeutics PHIO Phio Pharmaceuticals Corp SLS Sellas Life Sciences Group SNGX Soligenix SPPI Spectrum Pharmaceuticals TVTX Travere Therapeutics CDTX Cidara Therapeutics MBRX Moleculin Biotech AG First Majestic Silver Corp AL Air Lease AP Ampco-Pittsburgh ARM Arm Holdings plc American Depositary Shares CLB Core Laboratories NV DOV Dover EWTX Edgewise Therapeutics FBIO Fortress Biotech GRI GRI Bio HG Hamilton Insurance Group, Ltd. NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares PHG Koninklijke Philips NV ADR PI Impinj SPH Suburban Propane Partners LP SR Spire GUTS Fractyl Health, Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joseph Pantginis (HC WAINWRIGHT)